Liquid Biopsy Panel Expansion Enables Admera Health to Add Immunotherapy Prediction

Jan 18, 2019

|

Premium

NEW YORK (GenomeWeb) – Admera Health recently expanded the number of genes covered in its next-gen sequencing liquid biopsy assay, making it possible for the company to give a readout of microsatellite instability (MSI), which has become a crucial biomarker for cancer immunotherapies such as Merck's PD-1/PD-L1 inhibitor Keytruda (pembrolizumab).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Possible Effect of Border DNA Testing

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

Commission to Develop Report on Germline Editing

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

To Boost Productivity

The US Department of Agriculture presents a new blueprint for animal genomic research.

This Week in Genome Research

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.

Menu